Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
92 studies found for:    PCSK9
Show Display Options
Rank Status Study
1 Completed COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV—Infected Patients
Conditions: HIV Seropositivity;   Dyslipidemias;   PCSK9
Intervention:
2 Not yet recruiting PCSK9 Inhibitors in the Progression of Aortic Stenosis
Condition: Aortic Valve Stenosis
Interventions: Drug: PCSK9 Inhibitor [EPC];   Drug: Placebos
3 Unknown  Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.
Condition: Acute Coronary Syndrome
Intervention: Other: biological parameters dosage
4 Completed Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia
Condition: Familial Hypercholesterolemia
Intervention:
5 Completed Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance
Condition: Obesity
Interventions: Procedure: biopsy of muscle, of liver, and of adipose tissue;   Procedure: clamp euglycemic - hyperglycemic;   Behavioral: diet;   Other: biopsies for biological and genetic analyses
6 Completed Sex Hormones and Blood PCSK9 Levels
Condition: Hypercholesterolemia
Intervention:
7 Recruiting Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
Condition: Subjects With Hyperlipidemia, Dyslipidemia
Interventions: Drug: Repatha (Evolocumab);   Drug: Placebo
8 Unknown  A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab;   Drug: placebo
9 Active, not recruiting The Effect of Resistance Training on Proprotein Subtilisin Convertase Kexin 9 Level After Coronary Bypass Surgery
Condition: Coronary Artery Disease
Interventions: Behavioral: resistance training;   Behavioral: aerobic training
10 Recruiting Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
Condition: Nephrotic Syndrome
Interventions: Drug: Alirocumab;   Drug: Alirocumab placebo;   Drug: Atorvastatin
11 Completed An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
Condition: Atherosclerosis
Intervention: Procedure: Blood draw
12 Recruiting Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Condition: Type2 Diabetes Mellitus
Intervention: Drug: Evolocumab
13 Active, not recruiting Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects
Condition: Hypercholesterolemia
Interventions: Biological: AFFITOPE® AT04A+adjuvant;   Biological: AFFITOPE® AT06A+adjuvant;   Biological: Adjuvant without active component
14 Recruiting A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia
Condition: Homozygous Familial Hypercholesterolemia
Interventions: Drug: ALN-PCSSC;   Drug: Standard of Care
15 Not yet recruiting Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
Condition: Dyslipoproteinemias
Interventions: Drug: PCSK9 Inhibitor [EPC];   Drug: Standard lipid lowering therapy
16 Enrolling by invitation Effects of Corn Oil Plus Vitamin E and B6 on LIpids, PcSk9 and Endothelial Function
Condition: Atherosclerosis
Interventions: Other: Vitaminized corn oil;   Other: Olive oil
17 Recruiting Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults
Conditions: Lipoprotein Metabolism;   PCSK9;   Proteomics
Interventions: Dietary Supplement: EPA-rich fish oil;   Dietary Supplement: DHA-rich fish oil
18 Completed
Has Results
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
Condition: Hypercholesterolemia, Familial
Interventions: Biological: Evolocumab;   Biological: Placebo
19 Recruiting Vascular Effects of Alirocumab in Acute MI-Patients
Conditions: Coronary Vessel;   Coronary Circulation;   Atheroma; Myocardial
Interventions: Drug: Alirocumab 150 MG/ML;   Drug: Placebo
20 Not yet recruiting Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
Condition: Atherosclerotic Cardiovascular Disease
Interventions: Drug: Evolocumab;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.